Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,
EFC12522
Phase 3 small_molecule active
Quick answer
Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules, for Cancer is a Phase 3 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active